Compare · ELV vs YDES
ELV vs YDES
Side-by-side comparison of Elevance Health Inc. (ELV) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $85.23B, about 249.1x YDES ($342.1M).
- ELV has been more active in the news (8 items in the past 4 weeks vs 1 for YDES).
- ELV has more recent analyst coverage (24 ratings vs 0 for YDES).
- Company
- Elevance Health Inc.
- YD Bio Limited
- Price
- -
- -
- Market cap
- $85.23B
- $342.1M
- 1M return
- -11.34%
- -
- 1Y return
- +22.67%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 1
- Recent ratings
- 24
- 0
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- Director Ramiro G Peru bought $383,860 worth of shares (1,000 units at $383.86), increasing direct ownership by 9% to 11,908 units (SEC Form 4)
- CMS Proposes Medicare Advantage Audit Recoveries Reaching Back to 2018
- Elevance Health upgraded by Argus
- From Confusion to Clarity: Consumers See a Role for AI in Simplifying Healthcare, Elevance Health/Harris Poll Survey Finds
- AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.’s New Shelf Registration
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Digital Info Ofr Lavu Ratnakar sold $572,000 worth of shares (1,300 units at $440.00), decreasing direct ownership by 8% to 14,849 units (SEC Form 4)
- SEC Form S-3ASR filed by Elevance Health Inc.
- EVP & CFO Kaye Mark sold $4,658,357 worth of shares (10,584 units at $440.13) (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
Latest YDES
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
- SEC Form 4 filed by YD Bio Limited
- SEC Form 4 filed by YD Bio Limited
- YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
- CEO Shen Ethan Phd bought $48,895 worth of Ordinary Shares (12,700 units at $3.85), increasing direct ownership by 0.11% to 11,258,331 units (SEC Form 4)
- CEO Shen Ethan Phd bought $12,183 worth of Ordinary Shares (3,100 units at $3.93), increasing direct ownership by 0.03% to 11,245,631 units (SEC Form 4)
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute